All News

Investigators identify several potential first time risk factors of long-term outcomes in patients with HER2-positive breast cancer with or without a pathologic complete response.

Investigators are expected to share initial safety and efficacy data from a phase 1/2 trial assessing IMPT-314 as a treatment for aggressive B-cell lymphoma in the second half of 2023.

Prexasertib is currently under investigation as part of a phase 2 trial as a treatment for patients with platinum-resistant ovarian cancer, endometrial adenocarcinoma, and urothelial cancers.

The FDA requests additional information requiring time and resources extending beyond the current evaluation period for vic-trastuzumab duocarmazine in advanced HER2-positive breast cancer.

Hans Kristian Nugraha, MD, SpOT, and colleagues detail the potential benefits of an arthroscopic surgical approach through a case study of a patient with giant cell tumor of bone.

Treatment with 20 mg/m2 of lenalidomide in patients under 22 years old who have pilocytic astrocytomas and optic pathway gliomas appears to be safe and effective.

Among those with multiple myeloma, Hispanic patients may experience worse outcomes such as in-hospital mortality vs other ethnic groups.

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Lead study author Ruben Mesa, MD, discusses findings from the MOMENTUM trial assessing the use of momelotinib in the treatment of myelofibrosis.

Chung-Han Lee, MD, PhD, and colleagues discuss the case of a patient with renal cell carcinoma, touching on optimal treatments, toxicities, and other factors.

Findings from a phase 2 trial suggest that trabectedin plus radiotherapy is a tolerable treatment option in patients with myxoid liposarcoma despite yielding an unsatisfactory overall response rate.

C. Ola Landgren, MD, recaps a recent panel discussion of the rapidly changing treatment landscape in multiple myeloma, and prospects for future development.

A panel of experts discuss the updated results of the phase 3 CLEAR trial presented at the 2022 International Kidney Cancer Symposium.

Findings from the phase 1/2 MajesTEC-1 trial suggest that preemptively planning and promptly managing cytokine release syndrome with supportive care in patients with multiple myeloma treated with T-cell–engaging bispecific antibodies may be beneficial.

Preet M. Chaudhary, MD, and his medical team discuss graft-vs-host disease (GVHD) and their treatment experiences alongside a patient, Hector Cuevas.

An additional 5 years of adjuvant aromatase inhibition following initial therapy may improve survival outcomes among disease-free patients with postmenopausal breast cancer, according to results from the phase 3 AERAS study.

Although findings from a population-based meta-analysis suggest a greater risk of death in patients due to cancers diagnosed during pregnancy and postpartum, not all disease sites had the same risk.

The FDA requests additional data and a safety update regarding N-803 plus BCG as a treatment for patients with BCG-unresponsive non-muscle invasive bladder carcinoma.

PYX-201 is currently being investigated in a phase 1 trial in patients with solid tumors.

The next leap forward in breast cancer is identifying patients who would best benefit from a treatment de-escalation approach through the use of precision medicine.

Co-editor-in-Chief Howard S. Hochster, MD, discusses persistent obstacles to the effective use of biosimilars in clinical practice.

“Sometimes we have to advocate, but mostly we have to hire experts in our practice who can access these agents through free assistance programs, partial assistance, copay assistance, etc. That is an effort, a big part of the infrastructure and practices, to be able to access therapies.”

Findings from a nested case-control study may enable individualized colorectal cancer risk estimations for Hodgkin lymphoma survivors who receive radiotherapy plus procarbazine.

China’s National Medical Products Administration has also approved zanubrutinib as a treatment for patients with Waldenström macroglobulinemia based on findings from the phase 3 ASPEN trial.

A post hoc analysis of the phase 3 TITAN trial highlights an association between PSA decline and survival among patients with metastatic castration-sensitive prostate cancer who were treated with apalutamide plus androgen deprivation therapy.

Findings from the phase 3 ORIENT-31 trial support the use of sintilimab plus chemotherapy as a potential novel treatment strategy for those with EGFR-mutated nonsquamous non–small cell lung cancer.

The CAR T-cell product has a neoantigen-specific T-cell receptor that is located and classified via a T-cell receptor discovery platform.

Investigators of a phase 1/2 trial report that CAR T cells targeting disialoganglioside GD2 may result in long-lasting antitumor activity in young patients with high-risk neuroblastoma.

Treatment with socazolimab plus carboplatin and etoposide appears safe in patients with small cell lung cancer, according to preliminary phase 1 study findings.

Findings from a recent phase 1b study suggest that magrolimab plus azacitidine may be an “important addition” to the higher-risk myelodysplastic syndrome treatment landscape.